OREANDA-NEWS. On 24 March 2009 JSC „Grindeks” informed that development of medications for the anti-HIV / AIDS therapy group is not on the agenda. The decisions regarding the project “Combination of nucleid reverse transcriptase inhibitors with Mildronate® in anti - HIV / AIDS therapy” will be taken during the further business development.

At the moment “Grindeks” research activities are targeted on successful completion of the wide scope research program in cardiology, which is the main therapeutic group of company.

Chairman of the Council of „Grindeks” Kirovs Lipmans: „Rigorous business studies regarding Research and Development projects are evaluated every year. According to business strategy, investments in Research and Development are focused on projects that are already nearing completion and with high return.”

As informed previously, “Grindeks” engaged in project “Combination of nucleid reverse transcriptase inhibitors with Mildronate® in anti - HIV / AIDS therapy” in 2006.